Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 4, 2014, 131 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $408.12 to $109,651,973.50.

Highlighted Stocks Traded by Insiders:

TE Connectivity (TEL) - FREE Research Report

Donahue Joseph B who is EVP, COO & Pres Network Solut. at TE Connectivity sold 2,500 shares at $55.34 on Feb. 4, 2014. Following this transaction, the EVP, COO & Pres Network Solut. owned 19,544 shares meaning that the stake was reduced by 11.34% with the 2,500-share transaction.

The shares most recently traded at $54.45, down $0.89, or 1.64% since the insider transaction. Historical insider transactions for TE Connectivity go as follows:

  • 4-Week # shares sold: 4,999
  • 12-Week # shares sold: 11,912
  • 24-Week # shares sold: 11,912

The average volume for TE Connectivity has been 1.9 million shares per day over the past 30 days. TE Connectivity has a market cap of $22.7 billion and is part of the technology sector and electronics industry. Shares are down 0.02% year-to-date as of the close of trading on Tuesday.

TE Connectivity Ltd., together with its subsidiaries, designs and manufactures products that connect power, data, and signal automotive, energy, industrial, broadband communications, consumer devices, aerospace and defense, and healthcare industries. The stock currently has a dividend yield of 1.81%. The company has a P/E ratio of 17.2. Currently there are 4 analysts that rate TE Connectivity a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TEL - FREE

TheStreet Quant Ratings

rates TE Connectivity as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full

TE Connectivity Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Boston Beer Company (SAM) - FREE Research Report

Geist John C who is VP of Sales at Boston Beer Company sold 371 shares at $208.00 on Feb. 4, 2014. Following this transaction, the VP of Sales owned 820 shares meaning that the stake was reduced by 31.15% with the 371-share transaction.

The shares most recently traded at $204.49, down $3.51, or 1.72% since the insider transaction. Historical insider transactions for Boston Beer Company go as follows:

  • 4-Week # shares sold: 100
  • 12-Week # shares sold: 16,521
  • 24-Week # shares sold: 21,521

The average volume for Boston Beer Company has been 56,900 shares per day over the past 30 days. Boston Beer Company has a market cap of $1.8 billion and is part of the consumer goods sector and food & beverage industry. Shares are down 14.69% year-to-date as of the close of trading on Tuesday.

The Boston Beer Company, Inc. engages in the production and sale of alcohol beverages primarily in the United States, Canada, Europe, Israel, the Caribbean, the Pacific Rim, and Mexico. The company has a P/E ratio of 40.3. Currently there is 1 analyst that rates Boston Beer Company a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on SAM - FREE

TheStreet Quant Ratings

rates Boston Beer Company as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full

Boston Beer Company Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Office Depot (ODP) - FREE Research Report

Garcia C Elisa D who is EVP, General Counsel & Secy at Office Depot sold 37,500 shares at $4.80 on Feb. 4, 2014. Following this transaction, the EVP, General Counsel & Secy owned 333,312 shares meaning that the stake was reduced by 10.11% with the 37,500-share transaction.

The shares most recently traded at $4.72, down $0.08, or 1.69% since the insider transaction. Historical insider transactions for Office Depot go as follows:

  • 4-Week # shares bought: 35,587
  • 4-Week # shares sold: 41,064
  • 12-Week # shares bought: 35,587
  • 12-Week # shares sold: 194,514
  • 24-Week # shares bought: 45,087
  • 24-Week # shares sold: 276,735

The average volume for Office Depot has been 10.7 million shares per day over the past 30 days. Office Depot has a market cap of $1.4 billion and is part of the services sector and specialty retail industry. Shares are down 9.64% year-to-date as of the close of trading on Tuesday.

Office Depot, Inc., together with its subsidiaries, supplies office products and services. The company has a P/E ratio of 39.8. Currently there are 4 analysts that rate Office Depot a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ODP - FREE

TheStreet Quant Ratings

rates Office Depot as a

hold

. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, impressive record of earnings per share growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including poor profit margins and weak operating cash flow. Get the full

Office Depot Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Valeant Pharmaceuticals International (VRX) - FREE Research Report

Provencio Norma Ann who is Director at Valeant Pharmaceuticals International sold 5,000 shares at $136.23 on Feb. 4, 2014. Following this transaction, the Director owned 147,206 shares meaning that the stake was reduced by 3.29% with the 5,000-share transaction.

The shares most recently traded at $133.03, down $3.20, or 2.41% since the insider transaction. Historical insider transactions for Valeant Pharmaceuticals International go as follows:

  • 4-Week # shares bought: 2,536
  • 4-Week # shares sold: 5,000
  • 12-Week # shares bought: 190,283
  • 12-Week # shares sold: 5,000
  • 24-Week # shares bought: 251,315
  • 24-Week # shares sold: 19,000

The average volume for Valeant Pharmaceuticals International has been 1.2 million shares per day over the past 30 days. Valeant Pharmaceuticals International has a market cap of $44.4 billion and is part of the health care sector and drugs industry. Shares are up 15.47% year-to-date as of the close of trading on Tuesday.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. The stock currently has a dividend yield of 0.95%. Currently there are 9 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VRX - FREE

TheStreet Quant Ratings

rates Valeant Pharmaceuticals International as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and generally higher debt management risk. Get the full

Valeant Pharmaceuticals International Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

PTC (PTC) - FREE Research Report

Heppelmann James E who is President and CEO at PTC sold 25,000 shares at $34.19 on Feb. 4, 2014. Following this transaction, the President and CEO owned 494,924 shares meaning that the stake was reduced by 4.81% with the 25,000-share transaction.

Dibona Anthony who is EVP Global Support at PTC sold 9,000 shares at $34.19 on Feb. 4, 2014. Following this transaction, the EVP Global Support owned 49,396 shares meaning that the stake was reduced by 15.41% with the 9,000-share transaction.

The shares most recently traded at $34.38, up $0.19, or 0.57% since the insider transaction. Historical insider transactions for PTC go as follows:

  • 4-Week # shares sold: 110,663
  • 12-Week # shares sold: 135,620
  • 24-Week # shares sold: 160,620

The average volume for PTC has been 701,600 shares per day over the past 30 days. PTC has a market cap of $4.1 billion and is part of the technology sector and computer software & services industry. Shares are down 1.98% year-to-date as of the close of trading on Tuesday.

PTC Inc. develops, markets, and supports software products and solutions in the areas of computer-aided design (CAD), product lifecycle management (PLM), application lifecycle management (ALM), supply chain management (SCM), and service lifecycle management (SLM) worldwide. The company has a P/E ratio of 25.6. Currently there are 3 analysts that rate PTC a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PTC - FREE

TheStreet Quant Ratings

rates PTC as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, revenue growth, good cash flow from operations and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

PTC Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by

Zacks Investment Research

null